You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Justin Petrone covers consumer genomics, ancestry testing, and the microarray and biochip sector of the genomics market for GenomeWeb.
A consortium led by the Barcelona-based company recently received €150,000 in EU funding to bring the platform to market.
The effort, called INNO4COV-19, was awarded €6.1 million last month to support the commercialization of new diagnostics.
The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.
The scientists received backing in the form of a €2.4 million EU grant this month and have founded a company, called Biopix-T, to commercialize the platform.
The effort is one of 23 research projects selected as part of a new, €128 million EU package to combat COVID-19.
The company has also seen uptake of HemoScreen in Europe and Australia since PixCell began selling the portable hematology analyzer in those markets.
The prize, organized by the British innovation foundation Nesta, has assembled a series of workshops and support sessions to help prize competitors.
Unilabs Denmark, the local subsidiary of the European diagnostic services provider, will carry out antibody testing as part of the effort.
The Oslo-based company plans to develop a test that can identify high-risk individuals based on an epigenetic signature.
Data generated via the platform will be used to inform UK National Health Service policy.